Microneedles as the technique of drug delivery enhancement in diverse organs and tissues by Rzhevskiy, Alexey et al.
Microneedles as the technique of drug delivery enhancement in
diverse organs and tissues
Rzhevskiy, A., Thakur, R., Donnelly, R., & Anissimov, Y. (2018). Microneedles as the technique of drug delivery
enhancement in diverse organs and tissues. Journal of Controlled Release, 270, 184-202.
https://doi.org/10.1016/j.jconrel.2017.11.048
Published in:
Journal of Controlled Release
Document Version:
Peer reviewed version
Queen's University Belfast - Research Portal:
Link to publication record in Queen's University Belfast Research Portal
Publisher rights
© 2017 Elsevier B.V.
This manuscript version is made available under the CC-BY-NC-ND 4.0 license http://creativecommons.org/licenses/by-nc-nd/4.0/,which
permits distribution and reproduction for noncommercial purposes, provided the author and source are cited.
General rights
Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other
copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated
with these rights.
Take down policy
The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to
ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the
Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.
Download date:05. Apr. 2019
1 
 
Microneedles as the technique of drug delivery enhancement in diverse 
organs and tissues 
 
Alexey S Rzhevskiy1, Thakur Raghu Raj Singh2, Ryan F Donnelly2, Yuri G Anissimov3,* 
 
1 Institute of Molecular Medicine, Sechenov First Moscow State Medical University, 
Trubetskaya 8, 119991 Moscow, Russia 
2 School of Pharmacy, Queen’s University Belfast, Belfast BT97BL, UK  
3 School of Natural Sciences, Griffith University, Gold Coast, Queensland, 4222, Australia 
* Correspondence email: y.anissimov@griffith.edu.au, phone: +61755528496 
Running Head: Drug delivery with microneedles 
 
Abstract 
Microneedles is the technique of drug delivery enhancement, which was primarily designed for 
facilitating percutaneous drug delivery. Started from the development of simple solid 
microneedles, providing microporation of stratum corneum and therefore enhancement of topical 
drug delivery, for two decades the technique has progressed in various modifications such as 
hollow, coated, dissolving and hydrogel forming microneedles. In their turn, the modifications 
have resulted in new mechanisms of drug delivery enhancement and followed by the expansion 
of applicability range in terms of targeted tissues and organs. Thus, in addition to percutaneous 
drug delivery, microneedles have been considered as an efficient technique facilitating ocular, 
oral mucosal, gastrointestinal, ungual and vaginal drug administration. It is anticipated that the 
technique of microneedle-assisted drug delivery will soon become relevant for majority of 
organs and tissues. 
  
Keywords: microneedles, transdermal drug delivery, ocular drug delivery, oral mucosal drug 
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1. Introduction 
For the last two decades, microneedles have actively been investigated as a technique of physical 
enhancement of transdermal drug delivery. Originally, the purpose of this technique was to 
facilitate drugs in overcoming stratum corneum (SC), the outermost skin layer and a formidable 
barrier that is almost impermeable for large and hydrophilic molecules [1]. The investigation of 
microneedles provided an opportunity to deliver drugs with higher molecular weights and 
hydrophilicity within the skin or deeper to the underlying tissues, with a subsequent local 
accumulation and effect or further release into systemic circulation. 
The technique of microneedles is minimally invasive, commercially feasible and simple in use. 
Being located on a supporting base, microneedle arrays are conventionally applied with a patch, 
roller, applicator, or with an injection system in case of the hollow type, manually or with 
electric force. To date, there are five known methods whereby percutaneous drug administration 
can be achieved according to the type of microneedles: solid removable, dissolving, hollow, 
coated and hydrogel-forming [2]. The mechanism of drug delivery enhancement via solid 
removable microneedles is based on the creation of pores/holes in SC prior to, or combined with, 
the application of a drug onto the skin surface. Such pores/holes increase the conductance of SC 
and improve flux of the delivered drug. Among the five types of microneedles, solid removable 
is the original type which became a platform for the development of dissolving, hollow, coated 
and hydrogel-forming microneedles. In case of the hollow type, following the insertion of 
mironeedles into the tissue, a drug is injected through bores in the central part of microneedles. 
Coated microneedles contain a drug which envelopes their surface and is released after the 
microneedles have been inserted into a tissue. Dissolving microneedles, made of biodegradable 
materials, are loaded with drugs which release from the applied microneedles due to their 
degradation. Finally, the most recently investigated type, hydrogel-forming microneedles are 
composed of non-dissolving crosslinked hydrogels, which are carried by a drug-loaded adhesive 
patch. After such patch is applied to the skin surface, the hydrogel-forming microneedles are 
swelled by an aqueous media of the skin creating hydrogel conduits which facilitate the flux of 
drug deeper into the skin [3].  
Microneedles are made of numerous materials (silicon, ceramics, glass, sugars, biodegradable 
polymers, steel, etc.), and differ in length (25-2000 µm) and shape [4]. The listed variety of 
features and different types of mechanisms of drug delivery enhancement, provide the technique 
with a high range of applicability and make microneedles a focus of research in the field of 
transdermal drug delivery. However, in recent years researchers investigated the potential of the 
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technique to be extended to other organs and tissues such as oral cavity [5], gastrointestinal tract 
[6], nails [7] and eyes [8]. The essence of microneedle application is to mechanically break 
epithelial or fibrous biological barrier and therefore facilitate the delivered drug in overcoming 
the barrier and being further delivered to the targeted site of an organ or tissue (Figure 1). The 
aim of this review is to highlight the progress achieved in drug delivery with microneedles in 
diverse organs and tissues. 
 
Figure 1. Types of microneedles, step-by-step process of their application, and corresponding mechanisms of drug 
delivery across a tissue barrier. 
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2. Percutaneous applications of microneedles  
Skin is the most superficial organ which covers human body and primarily acts as a barrier, 
preventing the body from an excess water loss and protecting it from pathogenic agents coming 
from the environment. Also, due to its high barrier properties, intact skin significantly limits 
percutaneous permeation of topically applied drugs, and therefore is a serious obstacle for 
transdermal drug delivery as a route of drug administration. The properties of skin are defined by 
its anatomical and physiological organisation. 
Skin is composed of three layers, taking the order from the most superficial to the deep: SC, 
epidermis and dermis [9]. The first two layers (SC and epidermis) mainly comprise the cellular 
component with a relatively low cellular interspacing, are not vascularised and do not contain 
nerve endings. In contrast, the structure of dermis is mainly presented by a framework of protein 
fibers (collagen and elastin) with an aqueous gel between them. Such composition of the dermis 
mechanically reinforces the skin, and at the same time keeps it elastic. Further, the metabolism 
and innervation of entire skin is served by blood vessels and nerves located in dermis.  
Even though both SC and epidermis provide skin with the barrier functions [10], major 
contribution to the barrier properties of skin is presented by SC. The so-called brick and mortar 
structure of SC brings serious limitations to the transdermal and intradermal drug delivery [11]. 
Being composed of dead keratinocytes and intracellular matrix (often referred as bricks and 
mortar respectively),  the latter being mainly cholesterol, triglycerides and ceramides, SC has a 
lipophilic and dense structure (1.4 g/cm3) [12]. Due to the described structure, SC is almost 
impermeable for the drugs with molecular weight higher than 500 Da, and LogP out of the 1-3 
range. Moreover, transdermal flux is often below the effective point for drugs which satisfy the 
criteria for successful percutaneous permeation but have a high therapeutically effective dose. 
The technique of microneedles enables these limitations to be overcome, and reveal a high 
potential of skin as a route of drug administration by providing an opportunity to effectively 
deliver drugs with differing features. Furthermore, due to their micro-size, microneedles provide 
an opportunity to overcome the SC barrier without causing pain or damaging blood vessels 
which are situated in the reticular dermis (Figure 2). Overall, microneedles have successfully 
been tested in transdermal delivery of drugs from diverse pharmacological groups, and there are 
currently three principal mainstreams of investigation of microneedle-enhanced transdermal drug 
delivery (TDD): microneedles in cosmetology, microneedles in percutaneous vaccination and 
microneedles in insulin delivery. 
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Figure 2. Schematic representation of the conventional application of microneedles. Thus, the microneedles 
overcome the skin barrier without reaching blood vessels and nerves in reticular dermis (a). The cross section of the 
skin sample stained with hematoxylin and eosin, and disruption of the skin barrier created with a 700 μm solid 
microneedle (b) (Adapted from [13]). 
 
2.1. Microneedles in cosmetology 
The application of microneedles is safe and painless [14]. Further, even though it decreases the 
barrier function of skin, normally it does not induce bacterial contamination and long-term 
irritation, and the skin is restored within 1-3 days after being treated [15, 16]. Such advantages 
allow the application of microneedles onto delicate skin areas, particularly face, making the 
technique attractive for being used in cosmetology.  
The feature of microneedles to enhance transdermal drug delivery via overcoming the barrier of 
SC is widely investigated in cosmetology [17]. Cosmetically active ingredients are 
conventionally delivered intradermally by being applied onto the skin surface or injected with a 
syringe through a hypodermic needle. However, the technique of topical drug application usually 
does not provide a desirable effect due to a relatively low permeability of skin to majority of 
cosmeceuticals and injections with hypodermic needles are not the best option in terms of safety. 
Microneedles is an alternative which has the ability to effectively facilitate delivering drugs into 
the skin, being minimally invasive, painless and atraumatic. 
One of the most attractive advantages of the technique for being applied in cosmetology is the 
ability to facilitate the transdermal delivery of peptides and proteins most of which are almost 
impermeable through intact skin. The most significant features which define low permeation rate 
of proteins and peptides across intact skin are the high molecular weight, from several hundred 
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daltons for peptides and thousands daltons for proteins, and hydrophilic nature. The recent in 
vitro study by Mohammad et al. demonstrated the efficacy of application of solid removable 
microneedles for the enhancement of lysine-threonine-threonine-lysine-serine (KTTKS), 
melanostatin and rigin, the peptides with a high cosmetic relevancy and potential to skin 
rejuvenation [13]. Thus, melanostatin decreases the production of melanin in the skin, rigin 
provides the anti-inflammatory effect and KTTKS contributes to the production of collagen. The 
results demonstrated a forceful increment in delivery and distribution of melanostatin and KTTS 
over the skin. In case of rigin, only a slight difference between the passive and microneedle-
mediated intradermal delivery was observed. 
In addition to facilitating transdermal permeation of peptides for skin rejuvenation, solid 
microneedles have recently been investigated as a technique to enhance transdermal delivery of 
cosmeceuticals regulating hair growth. Thus, Kumar et al. demonstrated the effectiveness of 
solid microneedles to enhance transdermal delivery of eflornithine hydrochloride in vitro. 
Further, in vivo experiments with the preliminary application of a microneedle roller (192 
needles, 500 µm length) to the dorsal skin of mouse models, trimmed with an electric clipper, 
has significantly increased the effect of topically applied Vaniqa eflornithine hydrochloride 
(13.9%) cream in terms of hair growth depression [18]. The results were compared with hair re-
growth after chemical depilation, plucking and trimming without further pretreatment with 
microneedles (Figure 3). Therefore, it was assumed that the technique of the enhancement of 
eflornithine delivery with the microneedle roller may effectively facilitate the treatment of facial 
hirsutism. Also, more recently, it was  indicated that the converse effect can be achieved if the 
skin pretreatment with a microneedle roller is followed by the topical application of minoxidil, 
which resulted in hair growth stimulation in the clinical trials of androgenic alopecia treatment 
[19]. 
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Figure 3. The effectiveness of different techniques in terms of prevention of hair re-growth after its removal. The 
regimen of treatment with the eflornithine cream was: 2 times daily with the interval of 8 hours between two 
treatments, using 50 mg of the cream per treatment. Thus, among the tested techniques, maximal effectiveness in 
terms of hair re-growth prevention was demonstrated by microneedle pretreatment with further application of the 
eflornithine cream which highlights the effectiveness of skin pretreatment with solid removable microneedles in 
order to enhance transdermal drug delivery. (Retrieved with permission from [18]). 
Currently, solid microneedles are widely used in cosmetology as rollers and pens (Figure 4). 
Despite the advantages of solid removable microneedles, application of this technique may 
sometimes be associated with such side effects as pain, skin irritation and inflammation, 
especially in the procedures of percutaneous collagen induction [20]. Furthermore, the combined 
application of solid microneedles with topical drug treatment is a multiple-step process, and most 
of the applied drug stays on the skin surface and does not reach deep skin layers. The listed 
disadvantages of solid removable microneedles may be avoided by using dissolving 
microneedles, which are a promising tool for cosmetology. 
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Figure 4. Solid microneedles used in cosmetology and devices, providing their application. Diverse types of 
dermarollers are available on the market including light emitting diode (LED) MicroNeedling Rollers (a) [21]; 
Dermaroller® MF8 (b) [22]; solid microneedles from diverse types of Dermaroller®: C8 (c), CIT8 (d), MF8 (e) 
(Retrieved with permission from [23]); Dermapen ® (f) (image taken from a marketing PDF obtained from 
Dermapen ®) and a Dermapen tip (g) [24]. 
In the in vitro study by Park et al. [25] adenosine, commonly used as an ingredient of anti-
wrinkle products, was successfully delivered inside the skin with microneedles composed of 
hydrophilic biodegradable polymers: polyvinylpirrolidone (PVP) and PVP copolymerised with 
poly(ethylene glycol) dimethacrylate (PEGDMA) at 0.5 and 1 %. Being placed in PBS, such 
adenosie-loaded microneedles are dissolved in approximately five minutes. Further, the 
microneedles demonstrated a 150% higher rate of adenosine delivery inside the skin in 
comparison with the topical adenosine delivery through intact skin. Moreover, the non- 
copolymerised PVP microneedles and PVP-PEGDMA microneedles demonstrated different rates 
of mechanical strength and solubility. The PVP-PEGDMA microneedles with a concentration of 
PEGDMA at 1% demonstrated higher mechanical strength but lower dissolution in comparison 
with microneedles containing PEGDMA at 0.5 %, or PVP microneedles. Such investigation 
highlights the importance of a reasonable balance between the constituents of dissolving 
microneedles.  
More recently, dissolving microneedles were successfully applied as patches for the intradermal 
delivery of ascorbic acid (AA) and retinyl retinoate (RR) [26] in a clinical study with the purpose 
of wrinkle improvement in a crow’s feet area. Hyaluronic acid, dissolved at 15% in deionized 
water, was used as a biodegradable media of the microneedles. Patients were divided into two 
groups, and patients from each group received a 12-week treatment with one type of the patches: 
AA-loaded or RR-loaded. The patches were applied twice daily during the study. The results 
demonstrated a significant and similar rate of wrinkle improvement after treatment with both 
types of patches, and no adverse effects were observed during the study. The successful wrinkle 
reduction with AA-loaded hyaluronic microneedles was also demonstrated in the study by Lee et 
al. [27]. 
 
2.2. Microneedles in percutaneous vaccination 
Skin is the most extensive organ of a human immune system. It is full of antigen-presenting cells 
such as dendritic cells, macrophages and Langerhans cells, which are responsible for the 
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facilitation to the development of active immune response [28]. For this reason, percutaneous 
vaccination is effectively applied due to increased immune response and reduced minimally 
effective vaccine dose  in comparison with other routes available for vaccination [29]. Further, 
skin as a route of drug delivery is convenient for its superficial location, and therefore is used for 
the administration of most vaccines. However, the conventional percutaneous delivery of 
vaccines with hypodermic needle and syringe can cause needle phobias and, especially in mass 
vaccination campaigns, is associated with a huge amount of biohazardous waste and sharps, the 
need for a specifically trained staff and relatively high total cost [30-32]. Furthermore, such 
issues as the need for reconstitution of lyophilised vaccines with a diluent prior to injection, and 
high amounts of vaccine wastage in case of using multi-dose vials, bring additional 
disadvantages to conventional percutaneous vaccination. The microneedles provide an 
opportunity to overcome the listed issues, and so are widely studied by academics and are 
attractive for industries. 
The first study of vaccination via microneedles was performed by Mikszta et al. in 2002 [33]. In 
this study silicon flat-tipped microneedles, arranged in arrays, were applied to gently scratch the 
skin of mice making microabrasions combined with the topical application of plasmid DNA. 
Thus, 35 µg of DNA encoding firefly luciferase was dissolved in 25 µl phosphate buffered saline 
(PBS) and applied onto 1 cm2 of the shaved dorsal mouse skin, and then the treated area was 
scratched with microneedle arrays from 6 to 12 times to break SC barrier. As the comparison 
test, DNA PBS solution was applied onto the intact shaved mouse skin, and also injected 
intramuscularly and intradermally. The comparison between the results of intact skin gene 
treatment and gene delivery through microneedle-scratched skin demonstrated from 1000- to 
2800-fold increment in luciferase activity, which was considered as a successful expression of 
delivered genes, depending on the number of scratches (6-12, respectively). The results of 
luciferase activity due to microneedle-treated gene delivery were also significantly higher in 
comparison with intradermal (750-fold increase) and intramuscular injections (460-fold 
increase). The further comparison of gene delivery effectiveness via the compromised skin 
scratched 6 times and intramuscular, and intradermal injections, was related to the administration 
of 100 µg plasmid DNA encoding hepatitis B surface antigen in a mouse model. It was observed 
that DNA delivery facilitated by skin scratching induced a significantly greater immune response 
in comparison with intramuscular and intradermal injection. Further, in case of the gene delivery 
enhancement with microneedle-scratching only two immunisations were required to achieve 
100% seroconversion, while in case of intramuscular and intradermal injections the same amount 
of immunisations caused seroconversion only at 50% and 40%, respectively.  
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To date, different types of microneedles have been tested and have shown positive results in 
terms of the effectiveness in percutaneous vaccination. However, as vaccines are unstable when 
exposed to the environment, the technique of intradermal vaccine delivery through the 
pretreatment of skin with solid removable microneedles followed by vaccine application onto the 
skin surface does not provide an efficient vaccination. Moreover, it does not seem possible so far 
to reliably predict the amount of vaccine delivered to the skin compromised with removable 
microneedles. Therefore, the most promising types of microneedles for intradermal vaccination 
are coated and dissolving applied as patches, or hollow applied with injection systems [34], in 
which the amount of delivered drug is known [35]. Further, the significant feature of coated and 
dissolving microneedles is that they carry vaccines in a dried form which are released due to 
dissolution in dermis after the application of a microneedle patch. This reduces the need for 
vaccine reconstitution as one of the steps of conventional percutaneous vaccine administration. 
In case of vaccination via hollow microneedles, vaccines are administrated in a liquid form 
through the central bores of the microneedles. Also, vaccines stored in dried form within 
microneedle patches, which contain suitable constituents, are more thermostable. Such improved 
thermostability, indicated in the studies with microneedle patches containing influenza [36] and  
measles [37, 38] vaccines, provide an opportunity to reduce or even eliminate a cold chain 
conventionally required for transportation and storage of vaccines. 
The in vitro and in vivo animal studies demonstrated that the vaccine administration via 
microneedle patches leads to dose sparing due to improved induction of immune response in 
comparison with conventional subcutaneous and intracutaneous injections [39, 40]. Further, as 
the microneedle technique is considered minimally invasive, its application is not as painful and 
distressful as the application of hypodermic needles. In addition, microneedles are much safer 
than hypodermic needles. Microneedle patches are designed for disposable use and are unlikely 
to be used repeatedly as can potentially happen with syringes and hypodermic needles, especially 
in developing countries [41]. Even in the case of accidental contact with contaminated utilised 
microneedle patch the chance of infection is negligible, as microneedles penetrate skin with the 
force commensurate to pressing by a thumb [42].  Consequently, vaccination via microneedle 
patches reduces the risk of sharps, and requires minimum of skills for being implemented 
independently after a brief training. To date, the issue of microneedle-associated vaccinaton has 
been investigated in the studies with influenza [43-51], measles [35, 38], poliovirus [52, 53], 
rotavirus [40], adenovirus [37, 54-56], BCG [57], botulism [58, 59], tetanus [60], anthrax [58, 
61]  hepatitis B [62, 63] and C [64], HIV-1 [65] and other vaccines. Table 1 collates the in vivo 
studies implemented with humans and nonhuman primates as a study objects, which are of 
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particular interest at the current stage of investigations in the field of microneedle-associated 
immunisation  
In vivo subjects Microneedles Vaccine Ref. 
Humans Hollow Influenza [48, 49, 66-71] 
Poliovirus [72, 73] 
Varicella-zoster [74] 
Rabies [75] 
Solid removable 
Nonhuman primates  Poliovirus              [53] 
Measles [38] 
HIV-1 [65] 
Influenza [76] 
Solid removable Japanese encephalitis [77] 
Hollow 
Staphylococcus aureus [58] 
Botulism 
Anthrax 
Plague 
Table 1. Studies with humans and nonhuman primates as subjects of microneedle-mediated vaccination. 
Economic benefits of the technique are also significant, and are associated with both the low cost 
of manufacturing of microneedle patches and reduced cost of vaccination [78]. Microneedles are 
manufactured from low-cost polymers, metal and silicon, and other expendable materials which 
are used in small amounts. The average size (1 cm3) and weight (1 g) of a single microneedle 
patch is significantly smaller than the sizes of a vaccine vial, needle and syringe required for the 
administration of one vaccine dose, which makes the transportation of vaccine-loaded (coated or 
dissolving) microneedle patches very advantageous. Further, each vaccine-loaded patch contains 
a single dose of vaccine. It reduces the wastage of vaccines, a serious disadvantage of multi-dose 
vials [79]. In addition to the above, the lack of need for vaccine reconstitution in microneedle-
induced immunisation decreases the amount of required consumables, and therefore the price of 
procedure. Finally, the possibility of independent administration, or administration with the 
assistance of minimally trained staff results in significant reduction of expenses [42]. The listed 
advantages provide immunisation via microneedles with a high potential to reduce the overall 
cost of mass immunisation, and therefore make an official certification of the technique an 
important task. 
 
13 
 
2.3. Microneedles in insulin delivery 
In current medical practice a control of type 1 diabetes, and particular cases of the type 2 is 
generally achieved by hypodermic/ subcutaneous insulin injections [80]. While this practice has 
been proven successful, many patients find injections painful and inconvenient [81] necessitating 
research into alternative delivery methods. A topical delivery would have been attractive, but a 
very large molecular weight of insulin (5808 Da) precludes meaningful penetration through the 
intact skin. Microneedle assisted transdermal insulin delivery provides an opportunity for 
painless overcoming of skin barrier, which is extremely warranted by diabetic patients as insulin 
administration is a daily procedure for them, and therefore received a significant attention of 
researchers.  
As early as 1997 a skin perforating device was patented and suggested for facilitating 
transdermal delivery of insulin [82], but more consistent and fundamental research efforts in this 
direction started with the work of Martanto et al. [83]. Solid removable microneedles were 
investigate in this work for the delivery of insulin and it was demonstrated for the first time, 
using the hairless rat model in vivo, that the microneedles application allowed to increase skin 
permeability to insulin, which effectively reduced blood glucose, consistent with 0.05–0.5 U 
insulin injected subcutaneously. From the investigation of feasibility of simple removable 
microneedles, insulin delivery progressed to examination of dissolvable [84], hollow [80, 85], 
and most recently to hypoxia-sensitive vesicle-loading [86] microneedles. 
Ito et al. investigated dissolvable dextrin microneedles loaded with various doses of insulin [84]. 
The microneedles were applied to mice in vivo and it was demonstrated that pharmacological 
availabilities were for all doses above 90%. Investigation of the stability of insulin in the 
microneedle preparations established that the remaining insulin after 1 month of the storage was 
more than 98%. Overall this work demonstrated the usefulness of self-dissolving microneedles 
for the transdermal delivery of insulin [84].  
Davis et al. demonstrated the feasibility of arrays of hollow microneedles for the delivery of 
insulin [80]. Using hairless rat model it was proven that modified-LIGA process manufactured 
microneedles were sufficiently strong to pierce living skin without breaking. Insulin delivery 
through microneedles achieved blood glucose reduction to 47% of pretreatment values [80]. 
Blood glucose pharmacodynamics analysis of the experiments suggested that 50 mU of insulin 
was delivered by microneedles. It was therefore concluded that microneedles are an appropriate 
technique for continuous or possibly modulated administration over time [79]. This work was 
followed by investigation of hollow glass microneedles by Wang et al [85] where precise 
14 
 
insertion of needles was assisted with a rotary drilling device. Injections of fluorescently labeled 
insulin to hairless rat skin in vitro demonstrated weak fluorescence in the epidermis, suggesting 
that insulin penetrates slowly the dermal–epidermal junction and mostly remained within the 
dermis. It was concluded that regardless of the versatility of microneedles made from glass, 
clinical applications would be more practical from microneedles made from different materials 
and by different methods [85]. 
Dissolving microneedles were investigated by Fukushima et al as a tool for delivering insulin in 
dogs [87]. The insulin was loaded onto a patch with 100 chondroitin sulfate dissolvable 
microneedles and two to four patches were applied to shaved abdominal skin of dogs. It was 
established that the bioavailability of insulin from patches was greater than 70% on average. The 
insulin in patches demonstrated excellent stability with more than 99% recovered after 1 month 
[87]. It was concluded that the dissolvable microneedles are useful for immediate-acting insulin 
delivery which can be economically fabricated and used for minimally invasive delivery of 
insulin. The added usefulness of the work is that a larger animal models was used, providing 
insight into the scalability of the technique to human applications.    
Insulin as a model drug was used in experimental [88] and computational [89] investigations. In 
the first work the effect of removable microneedles insertion force on insulin penetration through 
porcine ear skin in vitro was investigated and it was concluded that that insufficient force 
markedly reduces the insulin flux through the skin regardless of the geometry of the 
microneedles [88]. The computational work [89] investigated insulin penetration using detailed 
numerical modelling using COMSOL software to identify the most efficient geometry of coated 
microneedles. It was concluded that microneedle penetration depth was the most significant 
factor in determining the flux of insulin.  
A very significant step in demonstrating the feasibility of hollow microneedles for the delivery 
of insulin in humans was the work of Gupta et al [90]. For the first time the insulin delivery with 
microneedles study was conducted in two adults with type 1 diabetes and compared insulin 
delivery with hollow microneedle to a catheter infusion. The study established that microneedles 
inserted to 1 mm provided the fastest insulin absorption and the best reduction of glucose levels. 
Importantly, the subjects reported no pain from microneedle insertion and there were no adverse 
reactions [90]. The same type of custom made glass hollow microneedles were used to 
investigate a pharmacokinetic and pharmacodynamic response to insulin injection in five type 1 
diabetes subjects [91]. It was concluded that intradermal insulin infusion using microneedles 
resulted in quicker insulin peak time (Tmax), about half the time than that of subcutaneous 
catheters, and also led to better reduction in plasma glucose levels. A larger clinical study with 
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29 type 1 diabetes subjects investigated intradermal insulin delivery using a 34-gauge 1.5-mm 
steel microneedle and compared it to standard subcutaneous delivery [92]. It was demonstrated 
that pharmacodynamic response was similar or better for intradermal vs subcutaneous delivery 
for immediately premeal and 17 min premeal infusions respectively. More recently, 
commercially available microneedle device (MicronJet600) was used to inject insulin to 
seventeen patients with type 2 diabetes [93]. In this study, similarly to the previous studies, a 
significantly shorter Tmax compared to subcutaneous injections were observed. Thus, the use of 
hollow microneedles for the delivery of insulin is well advanced and is now being tested 
clinically.   
An interesting approach of insulin delivery from positive nanovesicles driven by iontophoresis 
through the skin with microneedle-induced microchannels was investigated by Chen et al. [94]. 
Male guinea pig skin was used for the in vitro studies and male Sprague–Dawley rats were 
utilized for the in vivo investigation. Microchannels in the skin were created by applying slid 
microneedles and then the nanovesicles with positive zeta potential were driven through the 
microchannels with small electric current of 0.2mA/cm2 with an on/off ration of 1:1 and 
frequency of 100 Hz. The significance of the work is that the current application has a potential 
to provide additional modulation of the rate of delivery of insulin that is easy and can be 
controlled in real time.  
While removable and dissolving microneedles techniques were assessed for insulin delivery and 
found interesting, perhaps a more promising technique, capable of delivering meaningful 
amounts of insulin, with better control over the delivered amount and the rate of delivery, is 
using hollow or injectable microneedles. The latest significant progress in the microneedles 
techniques for insulin delivery is the use of patches loaded with hypoxia-sensitive vesicles that 
can provide fast automatic glucose-responsive insulin delivery [86]. This approach allowed 
glucose-responsive “closed-loop” insulin delivery system in which the local hypoxic 
microenvironment rapidly triggers the dissociation of vesicles and subsequent release of insulin. 
Another glucose-responsive system was based on a microneedle patch integrated with pancreatic 
β-cells in semi-permeable biomaterials combined with glucose signal amplifiers [95].  
Application of the cells using microneedles allowed their isolation from the immune system, 
while still allowing the diffusion of nutrients and oxygen to the encapsulated cells. The system 
was tested in vitro and in vivo in STZ-induced type-1 diabetic mice and demonstrated the 
potency of the microneedle patches for glucose regulation for a prolonged period [95]. These 
body-modulated and minimally invasive systems for delivery of insulin, if developed to a viable 
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product, will constitute a “holy grail” of control of type 1 diabetes that mimics the function of 
pancreatic cells. 
 
2.4. Microneedles in the transdermal delivery of a diverse range of high and low molecular 
weight drugs 
Currently, a limited number of drugs have been approved by FDA for transdermal drug delivery 
[96] mainly due to formidable barrier properties of SC. Potentially, the technique of 
microneedles can be applied for the enhanced delivery of all the approved drugs, being at the 
same time prospective for transdermal delivery of any other relevant high and low molecular 
weight formulations such as non-cosmeceutical peptides, oligonucleotides, DNA, desmopressin, 
oxytocin, human growth hormone, acyclovir, lidocaine, carnitine, botox etc [97-100]. Thus, it is 
anticipated that microneedle-mediated transdermal drug delivery may substantially increase the 
range of transdermally delivered drugs, which previously had no chance for being effectively 
delivered through this route of drug administration, and promising clinical studies have been 
conducted with the number of them. Over the past decade, there has been a substantial increase 
in research of MN technologies. Indeed, the number of academic publications on the subject has 
more than tripled since 2007. While biological agents have been the main focus, water soluble 
drugs not currently suitable for passive transdermal delivery are also of great interest. A number 
of companies are investing heavily in development of MN-based transdermal delivery systems. 
These include 3M, Corium, Zosano Pharma, Vaxxas, Nemaura, Becton-Dickinson, LTS 
Lohmann and NanoPass Technologies [101-108]. 
Currently, Zosano Pharma is developing transdermal delivery products based on the Macroflux® 
technology originally designed at Alza. Having apparently moved away from its initial focus on 
delivery of parathyroid hormone for management of post-menopausal osteoporosis, Zosano has 
recently announced successful results of a double-blind placebo controlled clinical trial focused 
on a delivery of zolmitriptan for treatment of migraine [101]. Further, Vaxxas is a venture 
capital-funded technology start-up company developing the coated MN Nanopatch™ technology 
that originated from Mark Kendall's research group at the Australian Institute of Bioengineering 
& Nanotechnology at The University of Queensland [102]. In 2015, Vaxxas announced that it 
had secured equity funding of $20 million from new and existing investors. These funds 
represented the first closing of a Series B venture financing round, the proceeds from which were 
to be used to advance a series of clinical programs and develop a pipeline of new vaccine 
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products for major diseases using Vaxxas' Nanopatch™ platform. This round of financing 
brought the total capital raised by Vaxxas to $33 million. 
 
NanoPass Technologies have shown their MicronJet™ device to be useful not only in the 
previously mentioned delivery of influenza vaccines (Table2), with the evidence of dose-sparing 
compared to conventional routes of immunisation, but also insulin [103]. However, it should be 
noted that this device is more similar to a small set of very short silicon needles attached to the 
barrel of a conventional syringe, rather than a true microneedle array. Meanwhile, Beckton-
Dickinson’s Soluvia™ device, consisting of a single 1.5 mm 30-gauge stainless steel needle on 
the end of a conventional syringe barrel, has been widely used for a number of years in Sanofi-
Pasteur’s market-approved intradermal influenza vaccine products Intanza® and Fluzone® [104]. 
3M’s microstructured transdermal systems (MTS), based on either hollow or coated solid MN, 
have been evaluated in a range of pre-clinical studies focussed on delivery of proteins, peptides 
and vaccines [105]. Nemaura Pharma, a specialist drug delivery firm based in the east Midlands 
in England, are developing MN systems for applications in cosmeceuticals, dermatology, 
analgesia, osteoporosis, immunology and oncology [106].  
Whilst the above mentioned MN devices have been based upon solid or hollow MN systems, it is 
envisaged that devices based upon FDA-approved, biodegradable/dissolving polymeric MN 
formulations will, in the future, receive increased attention from pharma companies. This is due 
to the self-disabling nature of such systems. Once inserted into skin, these MN will either 
dissolve or swell, thus making insertion into another patient post-removal virtually impossible. 
This will, therefore, reduce transmission of infection by preventing needlestick injuries 
associated with conventional needles. Disposal issues will also be bypassed, since there is no 
“sharp” remaining. Ultimately, the impact on healthcare in the developing world in particular 
could be significant. Encouragingly, Mark Prausnitz recently reported the first successful human 
clinical trial of a dissolving MN vaccine patch (Table 1) [76]. 
Corium has stated that they are exploring several applications of dissolving MN with pharma 
partners, with a particular current interest in delivery of human parathyroid hormone (hPTH) and 
zolmitriptan, with the hPTH project, using MN manufactured at Corium, now in Phase 2 clinical 
trials [108]. Most notably, perhaps, LTS Lohmann (LTS), the world’s largest transdermal patch 
manufacturer, have now entered into the MN field and are inviting partners to collaborate on 
development of new MN products based on such technology [107]. Given the manufacturing 
capabilities, expertise and customer base of LTS, it will be surprising if they do not claim a 
sizeable proportion of the developing MN market in the coming years. Indeed, LTS recently 
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announced that they now hold Europe’s first manufacturing licence for MN patches. Fujifilm 
also appears to have considerable manufacturing capability for MN patches, but they have not 
made any significant announcements since 2012 [109], 
It is notable that the companies publically engaged in MN development at present could all be 
reasonably categorised as “drug delivery” companies, or companies with a specialised drug 
delivery component. It is very unlikely that any of them will ever end up holding the product 
licence for a MN vaccine or drug product themselves. Their business models suggest that they 
would either sell their technology, or indeed the entire company, to a pharmaceutical company 
seeking to bring a MN product to the market or, alternatively, as may be the case with Corium, 
Fujifilm and LTS, the drug delivery company would act as the product manufacturer, with the 
product taken through clinical trials, regulatory scrutiny and ultimate product registration by a 
sponsoring pharma company. Rumours in the field abound about the involvement of big pharma 
companies in MN development. Indeed, GlaxoSmithKline hosted the 2016 Microneedles 
Conference in London. However, to date, involvement of major players has, perhaps 
understandably, been kept under wraps. It is possible that big pharma see MN as only a vaccine 
product suitable for the developing world from which they are unlikely to make money. 
Alternatively, they may not want to make their interest public for fear of “tipping off” 
competitors, or they may be unsure of the technology, but want to keep an interest by sponsoring 
work with academic groups or specialist MN firms, so as to avoid “missing the boat” if MN 
products were to be marketed by a competitor. Whatever the reasons, the financial muscle of a 
large company would certainly expedite the first MN-based drug or vaccine product’s route to 
market. There may be an alternative, of course. The Bill & Melinda Gates Foundation have 
invested heavily in development of MN vaccines [110]. For example, $6 million has recently 
been awarded to Vaxess to develop inactivated polio and live attenuated measles rubella 
vaccines [110]. PATH (formerly Program for Appropriate Technologies in Health) are now 
developing a Centre of Excellence in this area to focus on commercial development of MN 
delivery systems with applications in developing countries. The question remains here as to who 
will be the product licence holder, however. Whatever the route ultimately taken is, once the first 
MN drug or vaccine product is finally approved for human use, one could reasonably expect 
numerous other products to quickly follow suit. 
 
3. Ocular applications of microneedles 
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Eye is an organ responsible for perception of the visual world, which is associated with the 
reaction on light, color distinguishing and visual estimation of shape and distance. The 
perception of such vital information by the eye makes ocular impairments, most of which lead to 
blindness, highly devastating for a person [111]. Ocular diseases can be divided into two groups: 
diseases of an anterior segment of the eyeball which include the impairments of cornea, 
conjunctiva, ciliary body and lens, and diseases of the posterior segment which is comprised of 
the sclera, vitreous humor, retina, choroid and optic disc (optic nerve) [112].  
Drug delivery to the eye can be achieved via a number of routes such as systemic administration 
(e.g. oral and parenteral routes), intravitreal injections, surgical implantation of drug vehicles for 
sustained drug release into the ocular or periocular tissues, and targeted topical administration 
via injections and conventional topical applications [113]. Even though each of the routes is 
effective in particular diseases scenario, these routes of delivery have serious disadvantages and 
limitations. For example, blood-ocular barriers [114] significantly decrease the permeation of 
systemically administered drugs, necessitating high doses of medications which can be toxic or 
cause severe side effects. The surgical implantation of sustained release drug vehicles, as with 
any surgical intervention, is highly invasive and is performed only in absence of the effective 
alternatives.  
To achieve targeted drug delivery in the eye direct injections of medication is practiced using 
hypodermic needles – where injections are either given in the eyeball (e.g. intravitreal, 
intracorneal, subconjunctival and intrascleral injections) or into the tissues surrounding the eye 
(i.e. periocular injections). The injections provide more localised delivery of drugs to the 
targeted eye sites than systemic drug administration and are successfully used for a treatment of 
numerous ocular impairments of both anterior and posterior eye segments, especially such 
acute/chronic conditions as bacterial and fungal keratitis, uveitis, blepharitis, age-related macular 
degeneration, diabetic macular edema etc. However, ocular and periocular tissues are delicate, 
and it is preferable to avoid such highly invasive methods as injections with hypodermic needles 
which cause significant discomfort to a patient and damage to the tissues of the eye. Further, 
ocular injections with hypodermic needles have such limitations as the possibility of intraocular 
pressure increment, bacterial invasion, mechanical tissue damage, inflammation, retinal 
detachment and local hemorrhage. Furthermore, the method of intraocular injections is 
technically challenging and requires skilled medical staff. The conventional topical 
administration with a liquid drug forms (i.e. ointments, gels, solutions) is generally useful in 
treatment of the anterior segment of the eye, can be self-administered and thereby demonstrate a 
high patient compliance. However, it is often difficult to achieve a therapeutic effect with eye 
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drops or ointments due to such limitations as a lacrimal fluid which washes away and can bind 
the drug applied onto the eye surface, and the barrier properties of cornea. Furthermore, in the 
conventional topical treatment, some amount of applied drug may be released into the vessels of 
a highly vascularized conjunctiva, which decreases bioavailability of the drug even more and 
potentially leads to the undesired systemic effects of the drug. 
Considering the listed features of the drug administration routes used in ocular treatment, the 
technique of microneedles has recently been proposed as a reasonable minimally invasive 
alternative [115]. The technique of microneedles has been investigated as the enhancing 
technique of treatment of both anterior and posterior eye segments [116]. The related studies 
have indicated microneedles of coated, dissolving and hollow types as promising in the field of 
ocular drug delivery. Thus, in ocular treatment microneedles are conventionally applied to the 
cornea or sclera, or to the suprachoridal space (SCS). Such application facilitates the delivered 
drugs to overcome the corneal or scleral barriers and then to be deposited inside the tissues, or to 
be released inside the anterior or posterior eye segment [117]. Being minimally invasive, the 
technique reduces pain, tissue damage and the possibility of bacterial contamination in 
comparison to the hypodermic injections. Further, the technique increases patient compliance by 
the possibility of self-administration, and decreases discomfort of the administration. Further, 
ocular treatment with microneedles is targeted, so its application overcomes physiological 
barriers of the eye and as a result is dose sparing and has higher bioavailability. However, even 
though the technique of microneedles is considered safe, it does not entirely satisfy the safety 
requirements of ocular interventions so far. Thus, the risk of microneedle fracture of non-
dissolvable microneedles within the eye is a major concern. The other important factor which has 
to be investigated is the effect of microneedle application on intraocular pressure. Even though 
little research has been done, the technique of microneedles has already been considered as 
promising in the field of microneedle-associated ocular treatment. Table 2 collates current 
progress achieved in the field of ocular applications of microneedles.  
Microneedles 
 
Chemicals, or 
Composites 
Experiment / 
targeted site 
Purpose Outcome Ref. 
Coated Sulforhodamine B 
BSAa  
Plasmid DNA 
 
In vitro / 
human sclera 
 
 
The first attempt to apply 
microneedles in ocular 
treatment to estimate the 
potential effectiveness of 
microneedles for drug 
delivery.    
Microneedles were inserted into the 
sclera for a short time of 20 seconds. 
Rapid dissolution and a subsequent 
forming of drug depot within the 
scleral tissue was indicated. 
[115] 
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Sodium fluorescein (SF) 
Pilocarpine 
In vivo / rabbit 
cornea 
The evaluation of the 
effectiveness of drug delivery 
via microneedles in the in 
vivo model. Moreover, safety 
examination in terms of post-
applicative inflammation and 
tissue damage. 
Microneedles were inserted into the 
cornea for 20 seconds in either cases 
with SF and pilocarpine. The drugs 
located on the microneedles’ surface 
were primarily dissolved into the 
corneal tissue and then being gradually 
released into the anterior eye chamber. 
As a result, the delivery of drugs via 
microneedles demonstrated 70-fold 
and 45-fold increase in drug 
concentration within the anterior 
chamber of the rabbit eye in case with 
SF and pilocarpine, respectively, in 
comparison to the topical drug 
administration. Further, it was 
indicated that the microneedle-
associated delivery of pilocarpine led 
to the rapid eye constriction. There 
was no inflammatory response 
indicated, and the created corneal 
abrasion disappeared after 3 hours, so 
the technique was considered safe to 
be used in ocular treatment. 
Hollow 
 
Sulforhodamine B 
Fluorescent 
nanoparticles and 
microparticles 
In vitro / 
human sclera 
The first attempt to apply 
hollow microneedles for the 
intrascleral delivery of drug 
solutions, and nanoparticle 
and microparticle 
suspensions. 
Overall, the results indicated hollow 
microneedles as appropriate to be used 
for the intrascleral delivery of drug 
solutes, nanoparticles and 
microparticles. There were two major 
investigations performed. First, the 
infusion of fluid was extremely low 
and in spite of various insertion depth 
or infusion pressure, only a partial 
retraction of a microneedle increased 
the flow rate. Second, differently from 
the delivery of nanoparticles, it was 
possible to deliver microparticles 
within the sclera only after it was 
exposed to hyaluronidase and 
collagenase which demolished the 
fibrous carcass of the tusssue. 
Therefore, only nano-sized particles 
[118] 
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were considered appropriate to be 
easily delivered within the sclera. 
Sulforhodamine B 
Fluorescent 
nanoparticles and 
microparticles 
Ex vivo / 
suprachoroidal 
(SCS) space 
of a human, 
rabbit and pig 
eyeballs 
The first attempt to provide 
the delivery of drug solution, 
and nano- and micro-particles 
within the SCS of the eye. 
The results indicated hollow 
microneedles as a suitable option for 
delivering drug solutions, and nano- 
and micron-sized particles within the 
SCS of the eye. Such delivery of nano- 
and micro-particles may potentially 
provide sustained drug release from 
SCS. Furthermore, the success in 
delivery of the particles within SCS 
was dependent on the spatial 
properties of microneedles and 
pressure applied to drive the particles 
through microneedle bores into the 
SCS. Thus, the most appropriate 
microneedle length was indicated at 
1000 μm and pressure at 250–300 kPa. 
[119] 
Sodium fluorescein 
Fluorescein 
isothiocyanate dextrans 
(40 – 250 kDa) 
Bevacizumab  
Particles (20 nm – 10 μm 
in diameter) 
 
 
In vivo / SCS 
of the rabbit 
eye 
To investigate a 
pharmacokinetics of the 
drugs and particles delivered 
within the SCS. 
The drugs and particles were 
successfully delivered within the SCS 
with a 750 μm hollow microneedle. 
Thus, the drugs were cleared after one 
day, while the particles remained 
within the SCS for two months. Such 
technique revealed a potential of 
hollow microneedles to deliver drug 
solutions and particles of a diverse 
size within the SCS for the rapid (with 
drug solution) or prolonged (with 
particles) treatment of posterior 
segment diseases. 
No post-procedure adverse effects 
were indicated.  
[120] 
Triamcinolone acetonide 
(TA) 
In vivo / SCS 
of a porcine 
eye  
To compare the effectiveness 
of anti-inflammatory therapy 
with TA between SCS 
microneedle injection and 
27G needle intravitreal 
injection. Further, the 
evidence of procedural 
adverse effects and drug 
According to the results, the 
microneedle-associated therapy of 
artificially-induced acute posterior 
uveitis model with 0.2 mg of the drug 
was the same affective as the 
intravitreal treatment of the model 
with 2 mg of the drug. There were no 
hemorrhage, drug toxicity, or 
[121] 
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toxicity, and intraocular 
pressure (IOP) were 
estimated. 
significant increase of IOP indicated. 
Nanoparticles (200 nm 
in diameter) 
Ex vivo / 
suprachoroidal 
(SCS) space 
of a human, 
rabbit and pig 
eyeballs 
First, to investigate the 
movement of injected 
nanoparticles within the SCS. 
Second, to determine barriers 
which hinder the 
circumferential flow of the 
particles in SCS and impact 
the ability to reach the 
targeted areas of SCS, as 
chorioretina is usually to 
evenly diseased.  
In rabbit eyes, the long posterior 
ciliary artery prevented the particles 
which are injected in the superior or 
inferior hemisphere from crossing into 
the other hemisphere. In human eyes, 
the barrier formed by the short ciliary 
artery hindered circumferential spread 
toward the macula and optic nerve. 
These results suggest that the 
anatomical barriers could hinder even 
spread of the administered drug or 
formulation within the SCS. Thus, it is 
essential to make a judicious selection 
of the injection region.  
[119] 
Bevacizumab Clinical trial To compare intrastromal 
delivery of bevacizumab via 
the microneedles with 
subconjunctival and 
conventional topical delivery 
with eye drops in terms of 
effective dose required to 
reduce corneal 
neovascularization. 
The technique of drug administration 
via the hollow microneedles was 
considered dose sparing. Thus, the 
delivery of only 4.4 µg of the drug via 
the microneedles caused the same 
therapeutic effect as the delivery of 
2500 µg and 52.500 µg with 
subconjunctival injections and eye 
drops, respectively. 
[122] 
 
 Fluorescein sodium In vitro / 
rabbit sclera 
The first attempt to use 
hollow microneedles (HMN) 
for the intrascleral delivery of 
in situ implant-forming gels 
HMN devices of different heights 
(400, 500 and 600 µm) were 
fabricated from hypodermic needles 
(27, 29 and 30G) and investigated for 
depth of penetration into rabbit sclera. 
Upon HMN injection, the gel turned 
into a semisolid implant and formed 
an intrascleral implant. Sustained 
release of fluorescein sodium was 
observed over 24 h and varied with the 
[123] 
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depth of implant delivery in the sclera. 
The results demonstrate that HMN 
device can localize in situ forming 
implants in the scleral tissue and 
sustain drug delivery. 
 Fluorescently tagged 
nanoparticles and 
microparticles 
In vivo / SCS 
of the rabbit 
eye 
To achieve targeted particle 
delivery by controlling 
polymeric formulation 
properties.   
Particles suspended in saline were 
distributed over 29-42% of the SCS 
upon injection. The addition of 
hyaluronic acid increased particle 
spread up to 100% of the SCS. 
Strongly non-Newtonian polymer 
solutions containing carboxymethyl 
cellulose or methyl cellulose 
immobilized particles at the site of 
injection for up to 2 months, which 
could enable targeted drug delivery to 
the ciliary body to treat glaucoma. 
This study demonstrates that targeted 
drug delivery via injection into SCS 
can be  controlled by using different 
polymeric formulations. 
[124] 
Dissolving Methotrexate In vivo / rabbit 
eye scleral 
pocket 
The investigation of 
pharmacokinetics of 
methotrexate released from 
surgically implanted 
biodegradable microneedles 
as a potential option to be 
used in vitreo-retinal 
lymphoma.  
The results indicated successful 
sustained release of methotrexate from 
the implanted microneedles. No 
postoperative adverse effects, or drug 
toxicity were observed. 
[125] 
 Fluorescein sodium 
Fluorescein 
isothiocyanate–dextrans 
(70 k and 150 k Da) 
In vitro / pig 
sclera and 
cornea 
The first attempt to 
investigate the feasibility of 
using polyvinylpyrrolidone 
(PVP) to fabricate MN and 
the potential of using 
dissolving PVP MN arrays to 
overcome barriers in ocular 
tissues and enhance ocular 
drug delivery.  
In vitro studies showed MNs 
penetrated into the ocular tissues could 
rapidly dissolve and form a depot 
within the tissues. These depots 
provided a sustained drug release into 
ocular tissues. Significant 
enhancement of macromolecular 
permeation across both the scleral and 
corneal tissues was observed when 
using MNs, in comparison to topical 
administration of aqueous solutions 
(Figure 5). The results from this study 
[126] 
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indicate that rapidly dissolving MNs 
could deliver macromolecules to the 
eye through the intrastromal or 
intrascleral route.  
Table 2. The significant investigations in the field of ocular treatment with microneedles  
 
 
Figure 5. Schematic representation of administration of PVP-based dissolving microneedles (MNs) – the left hand 
side represents the collection and processing of confocal images of scleral tissues following application of MN 
arrays, where (a) topical image of tissue after 5 min following insertion of MN array, (b) cross section image of 
tissue after 5 min following MN array insertion, (c) topical image at a depth of 80 µm from surface of the tissue 
after 1 hr following MN insertion, and (d) cross section image of tissue 1 hr after applying an aqueous drug solution 
(Retrieved with permission from [126]). 
 
4. Oral mucosal and gastrointestinal applications of microneedles 
Oral cavity and gastrointestinal tract are the second, after the skin, parts of a human body most 
exposed to xenobiotics. Furthermore, these parts are in periodic contact with endogenic enzymes 
and digestive products. Thus, the highly-resistive oral and gastrointestinal barrier mainly consists 
of a complex mechanical, chemical, microbal and immune barrier which provide adequate 
protection [127]. Drug permeation across oral and gastrointestinal mucosa is limited by the 
barriers of superficial mucus and deeper epithelial tissue, with the additional barrier of 
luminally-secreted and membrane-bound enzymes, which cover the underlying lamina propria 
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full of capillaries, nerve endings and immune cells [128]. Mucus, bound to the external site of 
epithelium, has a structure of hydrogel of approximately 83% water containing diverse inorganic 
compounds, proteins, lipids, carbohydrates and proteins with mucin as the main component 
mainly produced  by Goblet cells of the epithelium [129]. Mucin is represented by glycoproteins 
of diverse molecular weights ranging at 1-40 × 106 Da, and defines the 3D network of mucus 
determining its viscous properties [130]. The average thickness of mucus is at 70 and 80-200 μm 
for oral and intestinal mucosa, respectively [127]. The barrier of mucus does decreases 
permeation of macromolecular drugs across mucosa, and owing its complex chemical structure 
may contribute to degradation and alter concentration of the applied drugs. Further, mucosal 
epithelium, simple columnar in intestine and nonkeratinized stratified squamous in oral mucosa, 
acts as a physical barrier reducing passive diffusion of molecules with the radius over 15 Å. 
Barrier properties of the epithelium are principally based on a multi-layered structure with 40-50 
cell layers in oral mucosa, and tight junctions between epithelial cells and lamina propria in 
intestinal mucosa. 
Numerous drug delivery systems were previously developed for providing enhanced delivery 
across oral and gastrointestinal barriers, and shield orally administered drugs from enzymes 
presenting in oral cavity and gastrointestinal tract [131-136]. Among such enhancing techniques, 
microneedles is the youngest option suggested so far. Thus, microneedles have already been 
investigated in the studies of oral mucosal vaccination, oral cancer management and 
gastrointestinal drug delivery by a microneedle-equipped pill. 
 
4.1. Microneedles in oral mucosal vaccine delivery 
Microneedles were clearly designed originally to enhance delivery of therapeutic or prophylactic 
substances into or across the skin. However, the predominant use of microneedles as vaccine 
delivery devices has recently prompted several researchers to consider targeting vaccines to the 
oral mucosa, in addition to the skin. Mucosal sites are typically rich in professional antigen-
presenting cells and vaccination at one mucosal site often provokes mucosal immune responses 
at distant sites, thus providing more complete immunity. This is especially important, since most 
pathogens enter the body through the mucosa. The mucosa in the oral cavity are easily accessible 
and have been used for many years as a site for delivery of systemic therapeutics, for example 
prochlorperazine for management of nausea and vomiting and nicotine for smoking cessation. 
Since vaccine antigens and adjuvants are typically large molecules, often with appreciable water 
solubility, they do not typically traverse the lipid barrier of the oral mucosa efficiently. 
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Reversible disruption of this barrier using microneedle devices represents one possible strategy 
for enabling oral mucosal vaccine delivery, facilitating transport of the vaccine to the antigen-
presenting cells of the viable tissue. 
Wang et al. [137] aimed to develop an effective, convenient and stable mucosal vaccine against 
hepatitis B virus (HBV). Mannose-PEG-cholesterol/lipid A-liposomes (MLLs) loaded with 
HBsAg were prepared by emulsification-lyophilisation, filled into microneedle moulds and dried 
to form proHBsAg-MLLs microneedle arrays (proHMAs). These proHMAs were stable, even at 
40 °C for up to 3 days and possessed sufficient mechanical strength to pierce porcine skin. Upon 
hydration, the microneedles rapidly dissolved, recovering the HBsAg-MLLs without obvious 
changes in size and antigen association efficiency. Immunisation of mice by a single application 
to the oral mucosa robust systemic and widespread mucosal immune responses, as evidenced by 
high levels of HBsAg-specific immunoglobulin G (IgG) in the sera and immunoglobulin A (IgA) 
in the salivary, intestinal and vaginal secretions. In addition, a strong cellular immunity against 
HBV was established through a mixed Th1/Th2 response, as confirmed by a significant increase 
in CD8(+) T cells, as well as enhanced levels of IgG2a and IFN-γ in the treated mice. The 
authors concluded that this novel microneedle system could be used to induce a multi-modal 
immune defence against HBV infection and may, in due course, be shown to enhance storage 
stability at elevated temperatures, thus obviating the expensive and inconvenient cold chain. 
Further, almost identical, work by the same Group (Zhen et al. [138]) prepared mannose-PEG-
cholesterol (MPC)/lipid A-liposomes (MLLs) entrapping model antigen bovine serum albumin 
(BSA), again using emulsification-lyophilisation. ProMLL-filled microneedle arrays were 
inserted into the oral mucosa of mice and elicited robust systemic and mucosal immune 
responses against the loaded antigen, as evidenced by high levels of BSA-specific IgG in the sera 
and IgA in the salivary, intestinal and vaginal secretions of mice. Enhanced levels of IgG2a and 
IFN-γ in treated mice revealed that proMMAs induced a mixed Th1/Th2 response. Moreover, a 
significant increase in CD8(+) T cells confirmed that strong cellular immunity had also been 
established. 
Ma et al. [139] sought to evaluate the feasibility of using coated microneedles to deliver vaccines 
into the oral cavity to induce systemic and mucosal immune responses. Microneedles were 
coated with sulforhodamine (Figure 6), ovalbumin and two HIV antigens. Coated microneedles 
were inserted into the inner lower lip and dorsal surface of the tongue of rabbits (Figure 7). 
Histology was used to confirm microneedle insertion, and systemic and mucosal immune 
responses were characterized by measuring antigen-specific IgG in serum and IgA in saliva, 
respectively. Histological evaluation of tissues showed that coated microneedles could penetrate 
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the lip and tongue to deliver coatings. Using ovalbumin as a model antigen, it was found that the 
lip and the tongue were equally immunogenic sites for vaccination. Importantly, both sites also 
induced a significant secretory IgA in saliva, compared to pre-immune saliva. Microneedle-
based oral cavity vaccination was also compared to the intramuscular route using two HIV 
antigens, a virus-like particle and a DNA vaccine. Microneedle-based delivery to the oral cavity 
and the intramuscular route exhibited similar yet considerable levels of antigen-specific IgG in 
serum. However, only the microneedle-based oral cavity vaccination group stimulated a 
significantly higher antigen-specific IgA response in saliva. 
 
Figure 6: Sulforhodamine-coated 1D microneedle arrays. Array visualized using (a) brightfield microscopy, and (b) 
fluorescence microscopy. Scale bar indicates 500 µm (Adapted from [139]). 
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Figure 7: Insertion of sulforhodamine-coated 1D microneedle arrays in rabbit oral cavity tissues. 1D array held in a 
Kelly locking forcep inserted into (A) stretched lower lip and (B) tongue. Regular array of dots formed by insertion 
of coated microneedles into rabbit (C) lip and (D) tongue (Adapted from [139]). 
 
4.2. Microneedles in management of oral cancer 
Oral cancers and precancerous dysplasias are sometimes diagnosed in a non-invasive fashion 
using optical coherence tomography (OCT), which can basically be described as the optical 
analogue of ultrasound imaging. Contrast in OCT images can be enhanced by utilising surface 
plasmon resonant gold nanoparticles (Au NP). To improve the poor in vivo transport of gold 
nanoparticles through biological barriers, an efficient delivery strategy is needed. Kim et al. 
[140] showed improved penetration and distribution of gold nanoparticles in induced dysplasias 
of the oral mucosa of hamsters in vivo following combination treatment with microneedles and 
ultrasound. CR3 roller microneedles (MTS dermaroller with miniscule holes of 70-μm diameter 
and 300-μm depth; Clinical Resolution Laboratory, Inc., Beverly Hills, CA) were rolled on both 
the DMBA-untreated and DMBA-treated sides of the hamster cheek pouches three times at three 
different angles (i.e., 0 deg, 45 deg, and 90 deg). A aliquot (200 μL) of anti-EGFR antibody-
conjugated PEGylated Au NP suspension (1.78 × 1010 particles/mL) was applied to the hamsters’ 
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cheek pouch for 10 min by dropping it directly into the 1-cm-diameter aperture of a ring-shaped 
clamp. After the Au NP topical administration, 0.3 W/cm2 of 1-MHz ultrasonic force was 
applied to the cheek pouch using the Dynatron 125 ultrasonicator (Dynatronics Corporation, Salt 
Lake City, UT) for 1 min. It was demonstrated that this multimodal delivery of antibody-
conjugated PEGylated gold nanoparticles enhanced the contrast in in vivo OCT images of oral 
dysplasia in a hamster model (Figure 8). 
 
Figure 8. In vivo SD-OCT images of (a) normal, and (b) dysplastic hamster cheek pouches. MN = microneedle 
treated; Au NPs = gold nanoparticles administered; US = ultrasound applied (Retrieved with permission from 
[140]). 
A reasonable question would be whether, in buccal tissues, after insertion and removal of coated 
microneedles, the presence of saliva over the insertion site can lead to loss of the deposited drug 
or vaccine and if saliva can influence permeation across the tissue. Serpe et al. [5] coated 
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microneedles with the model drug sulforhodamine (SRD) and inserted them into porcine buccal 
mucosa in vitro. Fluorescence microscopy was used to study microneedle coating quality and the 
diffusion of SRD through the mucosa. Permeation experiments were conducted for simulated 
dynamic or static salivary flow by adding 100 μL/h or 100, 200 or 300 μL of phosphate buffered 
saline (PBS) in the donor compartment of Franz diffusion cells, into which buccal tissue after 
insertion of SRD-coated microneedles was placed. Microscopy showed that microneedles were 
uniformly coated with SRD and that SRD was successfully delivered into the mucosa. Some 
SRD remained in the tissue even after 24h, despite presence of PBS on top of the coated 
microneedle insertion site. It was found that salivary washout can possibly result in loss of 
drug/vaccine that has been deposited in the oral cavity mucosal tissues using coated 
microneedles and presence of fluid over the coated microneedle insertion site can increase flux 
across the tissue. Thus, it is advisable to include salivary flow during developmental in vitro 
studies related to the use of coated microneedles for drug delivery to the oral cavity in order to 
not obtain misleading results. 
 
The small number of studies carried out to date suggest that microneedles may well be a viable 
delivery system for delivery of vaccines and possibly also drug substances across the mucosal 
barrier in the oral cavity. It would be interesting, however, to see how such systems perform in 
human volunteers. Pain may possibly be an issue, given the sensitive nature of the mucosa. It 
will be crucial that microneedles are not exposed to significant amounts of saliva prior to 
insertion, since this will initiate drug release before it is required and may also compromise the 
ability of polymeric microneedles to subsequently penetrate the mucosal barrier. If sustained 
drug delivery is required, the microneedle baseplate will need to exhibit mucoadhesive properties 
to keep the needles in place, with the reverse of the device coated with a moisture-impermeable 
backing layer to resist early dissolution. Safety is another consideration, since the mucosal cavity 
is replete with microorganisms. Passage of such across a compromised mucosal barrier would be 
undesirable, due to the possible risk of local or systemic infection.  As more studies are 
published and the technology evolves, industry may well become interested. This will be 
essential for progression of the technology to commercial return on investment and, importantly, 
patient benefit. 
 
4.3. Microneedles in gastrointestinal delivery 
It is well known that both patients and healthcare professionals generally prefer the oral route of 
drug delivery. The gastrointestinal (GI) tract, however, limits the bioavailability of certain 
therapeutics because of its protease and bacteria-rich environment, as well as general pH 
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variability from pH 1 to 7. These extreme environments make oral delivery particularly 
challenging for the biologic class of therapeutics, the absorption of which is further 
compromised by their high molecular weights. The Langer Group [6] demonstrated proof-of-
concept experiments in pigs that microneedle-based delivery (Figure 9) has the capacity for 
improved bioavailability of a biologically-active macromolecule, namely insulin. The authors 
showed that microneedle-based devices can be passed and excreted from the GI tract safely. The 
basic theory is that the contraction of the smooth muscle of the small intestine causes the hollow 
metal microneedles to penetrate the mucosa, releasing the insulin from a central protective 
reservoir thought the lumen of the microneedles and into the viable tissue for systemic 
absorption. 
 
Figure 9. A cylindrical microneedle “pill” for the oral administration of biologic drugs. (A) Computer-aided design 
of the radial prototype housing used for in vivo safety evaluation. (B) Finished prototype used for in vivo safety 
showing the metal endcap and pin. (C) Radiography of the prototype in (B). Pill length 2cm, diameter 1cm, needle 
gauge – 25G (Adapted from [6]). 
While it may at first seem that this technology will immediately revolutionise delivery of 
biological therapeutics, taking the needle out of the equation, caution must be exercised. The 
system relies on pressure within the lumen of the small intestine for insertion. This will clearly 
vary from one patient to another. Presence of food in the gastrointestinal tract will also lead to 
variation in penetration, especially if it is viscous or particulate (e.g. nuts) in nature. For a 
molecule such as insulin, which requires tightly-titrated dosing, such a delivery system could 
cause more problems than it solves. Should a patient have to take such “pills” regularly, variable 
absorption, and hence therapeutic response. is almost inevitable. Considerable further evaluation 
and development is clearly required before confidence in the safety, efficacy and reliability of 
this technology will be widespread. 
 
5. Nail applications of microneedles 
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Due to its convenience, opportunity to avoid systemic side effects, improved patient compliance 
and dose sparing, topical therapy has been a preferable technique in treating various nail 
diseases, particularly onychomycosis and nail psoriasis [141]. However, the effectiveness of 
topical drug applications onto nails is restricted due to low permeability of the applied drugs 
across nail plate, defined by the plate’s compact keratinized structure. Further, hindered drug 
permeation demands a prolonged presence of an applied drug formulation onto the nail plate, 
which often leads to the evaporation of a drug vehicle with the subsequent immobilisation of the 
drug. Thus, there is a need for facilitating techniques to achieve more efficient topical treatment 
of nail ailments [142].  
As an example of such technique, facilitating to ungual drug permeation, Chiu et. al proposed an 
original method of microneedles application [7]. Thus, a commercially available dermaroller, 
with microneedles at 250 μm long, was applied to fingernail clippings by being rolled down and 
forth for 5 times. The procedure was followed by topical application of Nile Red (NR) loaded 
within 5,10,15,20-tetrakis-(4-aminophenyl)-porphyrin (PCL) nanoparticles, or (TAPP) - labelled 
PCL nanoparticles loaded with methoxycinnamate (OMC). OMC was used as a model for 
terbinafine, a conventional remedy for treatment of onychomycosis [143]. The NR-loaded 
nanoparticles were also topically applied to intact nails and the results obtained from the cases 
with microneedle-treated and intact nails were compared. 
The depth of NR permeation from the PCL NPs through the nails was registered with laser 
scanning confocal microscopy (LSCM) and presented as a function of time (Figure 10). Thus, 
the permeation of NR across the nails treated with the dermaroller had a sbustantially higher rate 
in comparison with the intact nails. Further, a high intensity of NR fluorescence signal after a 
short-time from the start of the experiment (Figure 10 (b)), in the microneedle-treated nails, 
signifies a quick disposition of the NPs within the created micro-cavities. It was indicated that 
after 7 days of the experiment, NR released from the nanoparticles permeated through the nails 
treated with the dermaroller down to the depths of 70-90 μm (approximately 1/3 of nail’s 
thickness), while the uptake of NR in the experiments with intact nails was negligible. The 
experiments with TAPP-PCL nanoparticles loaded with OMC demonstrated similar results to 
those described above for the NR-loaded nanoparticles. Thus, the nanoparticles were primarily 
deposited within the created micropores, with a subsequent release of OMC and its diffusion 
within the nail. At the same time, no permeation of the nanoparticles through the nail was 
observed. Consequently, the application of solid removable microneedles to nail created micro-
cavities which acted as reservoirs for topically applied drug-loaded nanoparticles, providing a 
sustained release of the loaded drug during several days. These results indicate that the described 
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technique of nail poration, with a subsequent application of controlled drug delivery formulation, 
is a promising approach for further investigation. 
 
Figure 10. LSCM visualization of NR permeation across the nail, presented as the functions of time for intact (a) 
and microneedle-treated nails (b). Scale bar at 50 µm. Intensity of fluorescence versus nail depth for intact (c) and 
microneedle-treated (d) nails, presented as the functions of time (Retrieved with permission from [7]). 
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6. Summary and outlook 
In 20 years, drug delivery via microneedles has grown from a novel fancy idea [144] into a wide 
and rapidly developing research field. Being first successfully applied to the skin, microneedles 
have been further proposed for ocular, oral mucosal, gastrointestinal and ungual drug delivery 
enhancement, and as the most recent advancement – vaginal [145, 146]. It is anticipated that the 
range of various microneedle-associated applications will be gradually growing, involving other 
tissues and organs. At the current stage, the focus is on commercialisation of microneedle 
devices and integration of the existing microneedle-associated drug delivery methods into a 
clinical practice for skin applications, and demonstration of effectiveness of the drug delivery 
within other organs and tissues.  
To date, among the variety of diverse microneedle types and subsequent techniques of drug 
delivery, and variability of applications, only intradermal vaccine and drug delivery with the 
devices based on hollow microneedles such as MicronJet ® 600 (NanoPass Technologies Ltd, 
Ness Ziona, Israel) [147] and Soluvia ® (Becton Dickinson, NJ, USA) [148] has been approved 
by official regulatory authorities including FDA. In the field of percutaneous applications, there 
are several issues which determine the success of integration of microneedle-associated drug 
delivery, and the major of them are: patient/healthcare provider acceptability, patient safety, 
manufacturing and regulatory considerations, and clear evidence of consistent pharmacokinetics. 
Thus, the acceptability and safety of microneedle-mediated drug delivery primarily relies on 
such factors as reduced pain, stress and risk of transmitting infections and needle stick injuries, 
lower chance of misuse, feasibility for self-administration and improved acceptance for use in 
children. In the study by Birchall et al. [149], it was demonstrated that 100% of the public 
participants and 74% of the health care professionals considered the technique of microneedle-
mediated percutaneous dug delivery prospective. Also, a high level of acceptability was 
determined for microneedle applications in children [150].  Further, Norman et al. revealed the 
possibility of consistent self-administration once appropriate instructions are provided [42]. 
However, despite high patient compliance, a variety of issues still have to be addressed to enable 
microneedle-based delivery systems to move closer to commercialisation. Thus, for more 
successful and convenient self-administration, the systems should be provided with indicators of 
a successful skin penetration and administration of an appropriate amount of the delivered drug, 
and with informative labelling containing the information about usage and disposal. Further, the 
applications of microneedles in pediatric patients are recommended to avoid any reference to 
“needles”. 
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From a regulatory point of view, even though microneedles are considered minimally invasive 
and relatively safe, many safety aspects still should be addressed. Thus, it is known that 
microneedle applications result in disruption of skin barrier, by creating micro-pores in SC and 
micro-conduits in deeper skin layers, which recovers within few hours after microneedle removal 
[97, 151] preventing microbial penetration within the skin [152].  However, there is no 
information on the effect of multiple microneedle applications on skin barrier, which is 
especially relevant for the cases when microneedle devices of a multiple microneedle arrays are 
used to provide local drug delivery and therefore can be applied only to a limited skin area.  The 
investigations on barrier disruption and restoration are necessary in the fields of microneedle 
applications to other organs and tissues, as due to lower regenerative abilities of the related 
barriers the results are anticipated to be less positive in comparison with skin. It will be 
important if all types of microneedles are considered as injections rather than any other kind of 
delivery systems, since this will determine whether the final product will need to be sterilised 
and prepared under aseptic conditions. Possible allergic reactions related to microneedle 
applications are also of a great interest for the industry and researchers. Thus, there is a 
significant concern on possible side effects of polymers which reside within the skin, particularly 
for the scenario with dissolving microneedles as it leads to deposition of microneedle matrix 
within the tissue and its accumulation in case of multiple applications. Further, few cases on 
transdermal drug delivery enhanced by the application of solid removable microneedles were 
reported [153]. In the reported cases, topical application of cosmeceuticals onto the skin treated 
with solid removable microneedles resulted in hypersensitivity reactions, which to our opinion 
were caused by such factors as: the lack of medical supervision, unsterile nature of the applied 
formulations and the tremendous rate of enhancement of transdermal delivery of multiple 
excipients presenting in the formulations native for the scenario with solid removable 
microneedles (Figure 1) [154, 155]. 
A lack of understanding of pharmacokinetics of the delivered drugs, and therefore impossibility 
to predict their desirable and side effects, is another significant cause of a relatively slow 
integration of microneedles as the technique of drug delivery enhancement. Even though an 
efficient microneedle-mediated percutaneous drug delivery was demonstrated in large number of 
in vitro, in vivo and clinical studies, there is still not enough highly reliable evidence for massive 
integration of the technique into a practical use. Thus, there is a strong demand for objective 
mathematical models which would provide an understanding of how the delivered drugs act, 
being administered with that or another type of microneedles in diverse tissues and organs. An 
37 
 
important progress towards such understanding was recently achieved by Rzhevskiy et. al [156] 
with the development of straightforward and convenient model, and subsequent equation, 
describing transdermal delivery of topically applied drug through the skin treated with solid 
removable microneedles. Such model may be adopted for the cases, which satisfy the scenario 
for solid removable microneedles, with tissues other than skin. 
Another important issue which demands deeper investigation, to improve the range of practical 
usability of microneedles for drug delivery, is related to the optimisation of microneedles’ design 
[157, 158]. Currently, most of the studies in this field are again related to skin applications. Such 
studies can be divided into two groups: the group of fundamental investigations relevant for 
microneedles of different types, and the group of investigations specific for certain type of 
microneedles. The group of fundamental investigations address the problem of most successful 
skin piercing when microneedles are applied with an adequate force [88] and are made of an 
appropriate material [159]. Thus, it was found that the depth of microneedle insertion depends on 
such interrelated parameters as microneedle density [98, 160] and their distribution over a 
supporting base [161], length, tip radius, tip angle and base radius [162, 163]. A successful 
insertion of microneedles determines the amount of drug released from biodegradable [164] or 
coated microneedles, successful microporation of a tissue barrier for the scenario with solid 
removable microneedles, and prevention of leaking when the delivered drug is administered via 
injection through hollow microneedles. One more significant issue is the estimation of 
mechanical strength of microneedles as there is a possibility of needle fracture after being 
inserted into a tissue [165], which is especially important for the cases with microneedles of non-
dissolving materials as their failure within the tissue in in vivo or clinical applications may lead 
to a serious harm. For the scenarios with coated [89] and dissolving microneedles [166, 167], 
spatial properties are primarily investigated in terms of their effect on sustained drug release. It’s 
worth mentioning a recent study by Romgens et al. [168] where an optimal design for the patch 
with vaccine-loaded dissolving microneedles, providing the most effective induction of 
Langerhans and dendritic cells within the skin and therefore successful immunization, was 
modelled. 
Despite the substantial success achieved in understanding of the effect of microneedles’ design 
on drug delivery enhancement across the skin barrier, there are numerous challenges which have 
to be addressed for applications to diverse organs and tissues. For skin applications, such 
challenges are mainly related to the optimization of design for hollow and hydrogel-forming 
microneedles. Thus, even though it was demonstrated that hollow design provides a microneedle 
additional weakness and may lead to tissue occlusion of a bore opening, there is still not enough 
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of published evidence regarding the most optimal design for hollow microneedles [85]. At the 
same time, little is known about the influence of design on drug delivery enhancement for the 
case with the newest – hydrogel-forming type of microneedles. For applications to other organs 
and tissues, the investigation of relations between microneedle design and character of drug 
delivery enhancement is at its very beginning. It is obvious that the experience and knowledge 
obtained from the studies related to application of microneedles to skin should be taken into 
account for progressive development of the new trends in microneedle-mediated drug delivery, 
as the challenges which have to be addressed are in general similar to those for skin. At the same 
time, investigations of the drug delivery to a particular tissue have to be considered in a context 
with its specific anatomical and physiological properties. 
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